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Abstract Grb7, Grb10 and Grb14 comprise a family of adaptor
proteins that interact with numerous receptor tyrosine kinases
upon receptor activation. Between the pleckstrin homology (PH)
domain and the Src homology 2 (SH2) domain of these proteins
is a region of approximately 50 residues known as the BPS
(between PH and SH2) domain. Here we show, using purified
recombinant proteins, that the BPS domain of Grb10 directly
inhibits substrate phosphorylation by the activated tyrosine
kinase domains of the insulin receptor and the insulin-like
growth factor 1 (IGF1) receptor. Although inhibition by the BPS
domain is dependent on tyrosine phosphorylation of the kinase
activation loop, peptide competition experiments indicate that
the BPS domain does not bind directly to phosphotyrosine. These
studies provide a molecular mechanism by which Grb10 functions
as a negative regulator of insulin- and/or IGF1-mediated
signaling. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Grb10 is a member of a family of adaptor (non-catalytic)
proteins including Grb7 and Grb14 which have been identi¢ed
as putative downstream e¡ectors of activated receptor tyro-
sine kinases. Proteins in this family contain an NH2-terminal
proline-rich region, a Ras-associated-like domain, a pleckstrin
homology (PH) domain, a short region known as the BPS
(between PH and SH2) domain, and a C-terminal Src homol-
ogy 2 (SH2) domain. Multiple alternatively spliced forms of
Grb10 (K^j) have been cloned from mice, rats and humans
[1^6]. Grb10 isoforms have been shown to interact with the
insulin receptor (IR) and the insulin-like growth factor 1 re-
ceptor (IGF1R) [3^14], as well as with the epidermal growth
factor (EGF) receptor [1,12], the platelet-derived growth fac-
tor (PDGF) receptor [4,14], Ret [15] and the ephrin receptor
EphB2/ELK [16].
Two domains of Grb10 are capable of mediating an inter-
action with the IR: the BPS domain and the SH2 domain [2^
4,8,12]. The BPS domain of Grb10 has been demonstrated to
interact with the core tyrosine kinase domains of the IR and
IGF1R in a phosphorylation-dependent manner [12]. The iso-
lated SH2 domain of Grb10 has been shown to bind to the
phosphorylated C-terminal tail of the IR [8]. However, the
relevance of this interaction for full-length Grb10 (with the
BPS domain present) is questionable, since full-length Grb10
with a non-functional SH2 domain interacts with the IR to
the same extent as wild-type Grb10 [12]. Interestingly, the
isolated Grb14 SH2 domain, which is 72% identical in se-
quence to the Grb10 SH2 domain, does not interact with
the IR [17,18].
The role of Grb10 and Grb14 in insulin and IGF1 signaling
is controversial. Overexpression of human Grb10L in Chinese
hamster ovary (CHO) cells was shown to reduce insulin-de-
pendent phosphorylation of IR substrate 1 (IRS1) and dimin-
ish activation of phosphoinositide-3 kinase [2], providing evi-
dence that Grb10L negatively regulates insulin signaling.
Similarly, overexpression of Grb14 in CHO cells was found
to inhibit insulin-stimulated DNA and glycogen synthesis [17].
In another study, overexpression of Grb10K in mouse ¢bro-
blast cells inhibited IGF1- but not insulin-stimulated mitogen-
esis [10]. Paradoxically, other experiments with Grb10K have
shown it to be a positive regulator of both insulin- and IGF1-
mediated mitogenesis [14]. Microinjection into rat ¢broblasts
of a Grb10Q deletion protein containing the BPS domain (un-
known at the time) and the SH2 domain partially inhibited
insulin- and IGF1-stimulated cell growth [3], which could be
consistent with either a negative role for Grb10Q or a positive
role (BPS^SH2 acting as a dominant negative).
To better understand the functional consequences of the
physical interaction between the BPS domain of Grb10 and
the tyrosine kinase domain of the IR (IRK), we have mea-
sured the e¡ect of the BPS domain on the catalytic activity of
IRK in vitro using puri¢ed protein components. We demon-
strate that binding of the BPS domain to IRK directly inhibits
substrate phosphorylation. Inhibition of IRK by the BPS do-
main depends on phosphorylation of the IRK activation loop
(A-loop), yet the BPS domain does not appear to bind directly
to a phosphotyrosine in the A-loop. The BPS domain also
inhibited the catalytic activity of autophosphorylated (acti-
vated) IGF1R kinase (IGF1RK), but not the activity of au-
tophosphorylated ¢broblast growth factor receptor 1 kinase
(FGFR1K).
2. Materials and methods
2.1. Production of Grb10 proteins
Full-length Grb10Q (residues 1^536) and the wild-type and mutant
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(Arg462CLys) BPS^SH2 constructs (encoding residues 357^536)
were subcloned into expression vector pET21 (Novagen). All con-
structs were veri¢ed by DNA sequencing. Escherichia coli strain
BL21(DE3) was transformed with the plasmids and cultures were
grown in Luria broth at 37‡C to an OD600 of 0.8. Protein expression
was induced by addition of isopropyl L-D-thiogalactopyranoside (1.0
mM ¢nal) for 3 h at 30‡C. Bacteria were harvested by centrifugation,
resuspended in lysis bu¡er (20 mM HEPES (pH 7.5), 0.1% Triton,
1 mM phenylmethylsulfonyl £uoride, and Complete Protease Inhibi-
tor tablets (Boehringer-Mannheim)), and lysed by French press. The
lysate was centrifuged at 20 000Ug for 1 h and the supernatant was
collected. Proteins were puri¢ed from the soluble fraction using cat-
ion-exchange chromatography (Fractogel, EM Science), followed by
gel-¢ltration chromatography (Superdex-75, Pharmacia), and again by
cation-exchange chromatography (Mono-S, Pharmacia). Protein con-
centrations were determined using calculated extinction coe⁄cients
[19]. Proteins were stored at 4‡C at V10 mg/ml in 20 mM HEPES
(pH 7.5) and 200 mM NaCl.
The isolated Grb10 SH2 domain (both wild-type and the
Arg462CLys mutant) was obtained by mixing puri¢ed BPS^SH2
(4 mg/ml ¢nal) at room temperature with elastase (10 Wg/ml ¢nal)
for 2.5 h. The resulting proteolyzed fragments were puri¢ed by gel-
¢ltration chromatography (Superose-12, Pharmacia). A 12 340 Da
fragment was veri¢ed to be the SH2 domain (residues 429^533) by
mass spectrometry and NH2-terminal sequencing.
2.2. Production of IRK, IGF1RK, FGFR1K and Shc
IRK (residues 978^1283) and IRKJ (residues 956^1283) were ex-
pressed by recombinant baculovirus in Sf9 cells. IRK and IRKJ
contain the substitutions Cys981CSer and Tyr984CPhe [20]. IRKJ
contains in addition the substitution Tyr965CPhe. The IRK and
IRKJ mutants were generated using either the Altered-site II system
(Promega) or the QuickChange system (Stratagene). All constructs
were veri¢ed by DNA sequencing. Puri¢cation of IRK and IRKJ
was performed as described previously [20]. Tris-phosphorylated
IRK (IRK3P : pTyr1158/1162/1163) and tetra-phosphorylated IRKJ
(IRKJ4P : pTyr972/1158/1162/1163) were produced by incubation
with Mg-ATP followed by puri¢cation on an anion-exchange column
(Mono-Q, Pharmacia) [21]. The phosphorylation state of IRK was
monitored using native gel electrophoresis [22].
Tris-phosphorylated IGF1RK (prepared similarly to IRK3P) was
provided by S. Favelyukis and W.T. Miller (SUNY Stony Brook).
Puri¢ed, unphosphorylated FGFR1K from baculovirus-infected Sf9
cells [23] was provided by M. Mohammadi (New York University).
FGFR1K was autophosphorylated in vitro by mixing 375 Wl of
FGFR1K (V25 WM, pH 7.3) with 125 Wl of 80 mM ATP and 200
mM MgCl2 for 40 min at room temperature. Autophosphorylated
FGFR1K was then puri¢ed by anion-exchange chromatography
(Mono-Q, Pharmacia). The activity of autophosphorylated FGFR1K
was approximately 500 times that of unphosphorylated FGFR1K.
The recombinant baculovirus for full-length Shc (p52) was provided
by M. Mohammadi. The Shc protein, which contains an NH2-termi-
nal histidine tag, was puri¢ed from baculovirus-infected Sf9 cells to
s 90% purity using Ni-a⁄nity chromatography (Qiagen).
2.3. Peptide substrate and Shc phosphorylation assays
The peptide substrate KKLATGDYMNMSP was derived from
phosphorylation site Tyr727 of rat IRS1. The peptide was commer-
cially synthesized (Alpha Diagnostic Int.) and puri¢ed by high-per-
formance liquid chromatography (HPLC) on a C-18 reverse-phase
column (Vydac). The peptide identity was con¢rmed by mass spec-
trometry. Kinase assays were performed in triplicate in a water bath
maintained at 30‡C. Reactions were initiated by the addition of 12.5
Wl of a solution containing 400 WM ATP, 100 mM HEPES (pH 7.5),
40 mM MgCl2, 2 mM of the peptide substrate and [Q-32P]ATP to 12.5
Wl of a solution containing 0.2 or 0.4 WM of the appropriate kinase
and the appropriate form of Grb10 (full-length, BPS^SH2WT, BPS^
SH2R462K or SH2WT) at either 0, 2, 20 or 200 WM. Reactions were
terminated after 20 min by the addition of 25 Wl of 30% trichloroacetic
acid. The reactions were then centrifuged at 14 000Ug for 2 min, and
50 Wl aliquots were spotted onto 2.1 cm diameter phosphocellulose
paper discs (P81, Whatman). The discs were washed collectively three
times for 10 min with 0.5% phosphoric acid and rinsed once in ace-
tone. The discs were air-dried and placed in 1.5 ml tubes for scintilla-
tion counting. All measurements of kinase activity were performed
under initial rate conditions.
Shc phosphorylation assays were performed in triplicate at room
temperature. Reactions were initiated by the addition of 7.5 Wl of a
solution containing 600 WM ATP, 100 mM HEPES (pH 7.5), 5 mM
MgCl2, 26 WM Shc and [Q-32P]ATP to 2.5 Wl of a solution containing
1 WM IRKJ4P and BPS^SH2R462K at either 0, 5, 50 or 200 WM. Re-
actions were terminated after 10 min by the addition of 10 Wl of
Laemmli sample bu¡er (Bio-Rad). The reactions were then run on a
12.5% polyacrylamide gel. The gel was then dried and exposed to a
phosphor screen (Molecular Dynamics) for 1 h. The screen was
scanned by a Storm-820 phosphorimager (Molecular Dynamics),
and the resulting image was analyzed using ImageQuant software
(Molecular Dynamics) to quantify the intensity of the bands.
2.4. Gel shift assays
1 Wl of puri¢ed BPS^SH2WT, BPS^SH2R462K or SH2WT at 300 WM
was mixed with 1 Wl of IRK0P or IRK3P at 80 WM. For the peptide
competition assays, 1 Wl of puri¢ed BPS^SH2WT or BPS^SH2R462K at
200 WM was mixed with 2 Wl of IRK3P at 100 WM and 1 Wl of a tris-
phosphorylated A-loop peptide (AL3P) at 64, 320, 1600 or 8000 WM.
Mixtures were loaded onto 20% native PhastGels and electrophoresed
with the PhastGel system (Pharmacia). The gels were stained with
PhastGel Blue R. A peptide corresponding to residues 1156^1168 of
the IRK A-loop (DIYETDYYRKGGK) was synthesized on a 431A
Peptide Synthesizer (Applied Biosystems) and phosphorylated in vitro
by IRK3P. AL3P was puri¢ed by HPLC on a C-18 reverse-phase
column (Vydac). The phosphorylation state of the peptide was veri¢ed
by mass spectrometry.
3. Results
3.1. A functional SH2 domain is not necessary for the binding
of Grb10 to IRK
Based upon previously published data establishing that the
BPS and SH2 domains of Grb10 are capable of mediating an
interaction with the IR [2^4,8,12], we overexpressed and pu-
ri¢ed to homogeneity two forms of a Grb10Q deletion mutant
consisting of the BPS and SH2 domains (BPS^SH2). The ¢rst
form contains a wild-type SH2 domain (BPS^SH2WT) and the
second form contains an arginine to lysine substitution
(Arg462CLys) in the FLVR motif of the SH2 domain
(BPS^SH2R462K). This substitution has been shown to abro-
gate the interaction between the Grb10 SH2 domain and
the IR [12]. In addition, the isolated wild-type and mutant
SH2 domains (SH2WT and SH2R462K) were generated. At-
tempts to overexpress and purify the isolated BPS domain
were not successful, probably owing to protein folding di⁄-
culties.
We performed native gel shift experiments to monitor the
binding of the BPS^SH2 proteins (BPS^SH2WT and BPS^
SH2R462K) to IRK. IRK contains three autophosphorylation
sites (Tyr1158/1162/1163), all of which are located in the ki-
nase A-loop. The results shown in Fig. 1A demonstrate that
BPS^SH2WT and BPS^SH2R462K bind to the tris-phosphory-
lated, activated form of IRK (IRK3P) with approximately
equal a⁄nity and do not bind to unphosphorylated IRK
(IRK0P), consistent with previous yeast two-hybrid and gluta-
thione S-transferase pull-down experiments [12]. Mixing of
isolated SH2WT with IRK3P produced a smear on a native
gel (Fig. 1A, last lane), which suggests a low a⁄nity interac-
tion, while SH2R462K produced no shift or smear (data not
shown). These experiments show that the phosphotyrosine-
binding function of the SH2 domain is not required for
BPS^SH2 binding to IRK3P ; the BPS domain is su⁄cient
for this interaction.
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3.2. The BPS domain of Grb10 does not bind directly to an
IRK phosphotyrosine
Having established that the BPS domain binds to IRK in a
phosphorylation-dependent manner, we tested whether the
BPS domain interacts directly with one or more phosphotyr-
osines in the IRK A-loop by performing a peptide competi-
tion experiment using AL3P. As shown in Fig. 1B, AL3P up to
a concentration of 2 mM (40U molar excess over IRK3P) did
not disrupt the complex between BPS^SH2R462K and IRK3P,
indicating that the phosphorylated A-loop is not the primary
site of interaction between the BPS domain and IRK3P. Fur-
thermore, AL3P did not disrupt the binding of BPS^SH2WT to
IRK3P (Fig. 1B), providing additional evidence that the BPS
domain, not the SH2 domain, mediates the interaction with
IRK3P.
3.3. The BPS domain of Grb10 inhibits substrate
phosphorylation by IRK
To determine what e¡ect, if any, binding of the BPS do-
main to IRK3P has on tyrosine kinase activity, we performed
kinase assays in the presence of various amounts of BPS^SH2.
As shown in Fig. 2A, BPS^SH2WT inhibited substrate phos-
phorylation by IRK3P in a concentration-dependent manner.
Consistent with the gel shift experiments (which showed sim-
ilar binding), BPS^SH2R462K inhibited substrate phosphoryla-
tion to the same extent as BPS^SH2WT. The observed inhibi-
tion by BPS^SH2 is not simply due to substrate competition,
since BPS^SH2 is not a substrate of IRK as assessed by anti-
phosphotyrosine Western blotting and autoradiography (data
not shown).
The isolated wild-type SH2 domain had no e¡ect on IRK3P
substrate phosphorylation (Fig. 2A), either because of poor
binding (Fig. 1A, last lane) or because binding of the SH2
domain to the phosphorylated A-loop does not result in ki-
nase inhibition. This result indicates that the BPS domain of
the BPS^SH2 protein is responsible for the inhibitory e¡ect.
To verify that full-length Grb10Q (Grb10FL) also inhibits IRK
catalytic activity, we performed kinase assays in the presence
Fig. 1. The BPS^SH2 protein binds IRK3P but not an A-loop phosphotyrosine. (A) The ability of BPS^SH2WT, BPS^SH2R462K and SH2WT to
bind IRK0P and IRK3P was assayed by native gel shift as described in Section 2. The Grb10 proteins do not migrate into the gel due to their
high pI. IRK3P migrates further than IRK0P due to the additional negative charges provided by the phosphates. Mixing of BPS^SH2WT or
BPS^SH2R462K to IRK3P produced a new band (labeled ‘complex’) corresponding to the complex of BPS^SH2 and IRK3P. Mixing of SH2WT
with IRK3P results in the disappearance of the IRK3P band, but not in the appearance of a distinct band representing an SH2WT^IRK3P com-
plex. (B) AL3P was used to compete with IRK3P for binding to BPS^SH2. In each of the lanes of the non-denaturing gel, IRK3P and BPS^
SH2, either mutant (left panel) or wild-type (right panel), are at a concentration of 50 WM. The peptide concentrations are 0, 16, 80, 400 and
2000 WM.
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of various amounts of Grb10FL. The results presented in Fig.
2B show that Grb10FL, like the BPS^SH2 protein, also inhib-
its IRK3P substrate phosphorylation in a dose-dependent
manner.
To examine the e¡ect of the BPS domain on IRK phos-
phorylation of a bona ¢de protein substrate, we used Shc
(p52) as a substrate. Shc is recruited to the activated IR via
an interaction between the phosphotyrosine-binding (PTB)
domain of Shc and pTyr972 in the juxtamembrane region of
the IR [24,25]. Accordingly, an IR cytoplasmic protein that
includes the juxtamembrane region as well as the tyrosine ki-
nase domain was produced and tetra-phosphorylated
(IRKJ4P). As shown in Fig. 3, BPS^SH2R462K inhibited Shc
phosphorylation by IRKJ4P in a concentration-dependent
manner.
3.4. The BPS domain of Grb10 inhibits substrate
phosphorylation by IGF1RK but not FGFR1K
To begin to explore the kinase selectivity of BPS domain
inhibition, the e¡ect of the BPS domain on the catalytic ac-
tivity of IGF1RK and FGFR1K was examined. BPS^
SH2R462K inhibited the catalytic activity of autophosphory-
lated (activated) IGF1RK in a concentration-dependent man-
ner (Fig. 4), similar to inhibition of IRK3P (Fig. 2A), but did
not a¡ect the catalytic activity of autophosphorylated
FGFR1K (data not shown). The inability of BPS^SH2R462K
to inhibit autophosphorylated FGFR1K demonstrates that
the BPS^SH2 preparation is not deleterious to kinase activity
per se, and indicates that the BPS domain selectively inhibits
tyrosine kinase activity.
Inhibition of IGF1RK was not surprising because it is
V80% identical in sequence to IRK, and Grb10 has been
shown previously to interact with the IGF1R [3,7,9,10,12].
Although FGFR1K is only V40% identical in sequence to
IRK, its A-loop contains two tyrosines, Tyr653 and Tyr654,
which correspond to Tyr1162 and Tyr1163 in IRK. The ob-
servation that the BPS domain of Grb10 is neither able to
bind to nor inhibit autophosphorylated FGFR1K further sug-
gests that the primary interaction between the BPS domain
and IRK/IGF1RK is not through an A-loop phosphotyro-
sine.
4. Discussion
Previous studies have implicated the SH2 and BPS domains
of Grb10 as mediating the interaction with the activated IR
and IGF1R [2^4,8,12]. Although the isolated SH2 domain of
Grb10 has been shown previously to be capable of interacting
with the IR [4,8,12], two lines of evidence suggest that in full-
length Grb10 the BPS domain is primarily responsible for the
interaction. First, yeast two-hybrid experiments indicate that
Grb10Q proteins containing a wild-type SH2 domain or an
SH2 domain with a FLVR mutation (Arg462CLys) interact
with the entire IR cytoplasmic domain to the same extent [12].
In that study, the isolated BPS domain interacted less well
(V50%) with the IR cytoplasmic domain than did BPS^
SH2R462K, which could be explained by a di⁄culty in folding
of the BPS domain in the absence of the SH2 domain.
The second line of evidence comes from peptide competi-
tion experiments. Here we demonstrated that AL3P was non-
competitive against IRK3P for binding the BPS^SH2WT pro-
tein (Fig. 1B), indicating that any SH2^phosphotyrosine in-
teraction makes a negligible contribution to the overall bind-
ing of BPS^SH2WT to IRK3P. Moreover, phosphorylated
peptides derived from the juxtamembrane region, the A-loop
and the C-terminal tail of the IR did not have any signi¢cant
e¡ect on binding of Grb10Q to the full-length IR [4]. Taken
together, these studies suggest that the SH2 domain in full-
length Grb10 may not engage a phosphotyrosine in the IR
cytoplasmic domain, or if so, the interaction may be of minor
importance.
The peptide competition experiments with AL3P demon-
strate that the predominant mode of binding of the BPS do-
main to IRK is not via the phosphorylated A-loop (Fig. 1B),
suggesting instead that a binding epitope for the BPS domain
is exposed upon autophosphorylation of the A-loop. Crystal
structures of IRK0P (low activity) [20] and IRK3P (activated)
[21] reveal that the A-loop undergoes a major conformational
Fig. 2. The BPS domain of Grb10 inhibits peptide phosphorylation by IRK3P. (A) The activity of puri¢ed IRK3P was assayed in the presence
of the indicated concentrations of BPS^SH2WT (dark gray), BPS^SH2R462K (light gray) and SH2WT (white). Activity was assayed using 100 nM
IRK3P and 1 mM of peptide substrate (see Section 2). IRK3P activity in the presence of the Grb10 proteins is expressed as a percentage of the
activity of IRK3P alone (black). The mean and standard deviation are derived from triplicate experiments. (B) The same assay was performed
in triplicate using Grb10FL.
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change upon autophosphorylation. In the crystal structure of
IRK3P, pTyr1163 is observed to be the key phosphotyrosine
in stabilization of the A-loop conformation, followed by
pTyr1162 and pTyr1158 [21]. Inhibition by BPS^SH2 of the
three bis-phosphorylated A-loop forms of IRK correlates well
with the degree of A-loop stabilization a¡orded by autophos-
phorylation at the three sites (data not shown).
Based on the gel shift assays, the dissociation constant (Kd)
for the interaction between the BPS domain (in the BPS^SH2
protein) and IRK3P is estimated to be on the order of 1 WM.
Although its ligand has not been determined, the PH domain
of Grb10 presumably binds to the phosphorylated head
groups of phosphatidylinositol lipids [26]. Localization of
Grb10 to the membrane via the PH domain would signi¢-
cantly enhance the interaction between the BPS domain and
the activated IR by increasing the e¡ective concentration of
Grb10. It may be that di¡erent subsets of the various domains
of Grb10 family members (poly-proline, Ras-associated-like,
PH, BPS and SH2) are utilized depending on the particular
receptor tyrosine kinase that has been activated. For example,
the SH2 domain rather than the BPS domain mediates the
interaction of Grb10 with the EGF [1,12] and PDGF [4,14]
receptors.
Many proteins containing SH2 and PTB domains are re-
cruited to activated receptor tyrosine kinases. In general, the
phosphotyrosine recruitment sites are outside of the core ty-
rosine kinase domain of the receptors, in the juxtamembrane,
kinase insert and C-terminal regions. Since the BPS domain of
Grb10 has been shown previously [12] and in our studies to
interact with IRK and IGF1RK, the question arises as to
whether binding of the BPS domain to these kinases a¡ects
catalytic activity, either positively or negatively. The results
presented in this study (Figs. 2^4) demonstrate that binding
of the BPS domain to autophosphorylated IRK and IGF1RK
negatively a¡ects the ability of these kinases to phosphorylate
substrates. The e¡ect on catalytic activity was observed for
full-length Grb10Q as well as for BPS^SH2R462K.
Our ¢nding that the BPS domain of Grb10Q directly inhibits
IR and IGF1R substrate phosphorylation suggests that Grb10
could act as a negative regulator of processes dependent on
tyrosine phosphorylation by these receptors, such as mitogen-
esis and glucose uptake. This would be consistent with the
majority of Grb10 and Grb14 overexpression studies (Section
1). Moreover, in support of the inhibitory mechanism pro-
posed here, it has been reported that overexpression of
Grb10L in CHO cells partially inhibits insulin-stimulated ty-
rosine phosphorylation of IRS1 and signi¢cantly inhibits ty-
rosine phosphorylation of the p60 GAP-associated protein [2].
In another study, IGF1-stimulated phosphorylation of IRS1
and Shc was not a¡ected by Grb10K overexpression in p6 cells
[10]. In that study, although Grb10K inhibited IGF1-stimu-
lated mitogenesis, it did not inhibit insulin-stimulated mito-
genesis. This suggests that the di¡erences in substrate phos-
phorylation reported in these two studies [2,10] could be due
to the di¡erent Grb10 isoforms expressed and/or the cell line
used.
We would anticipate that Grb10, acting as an inhibitory
binding protein for the IR and IGF1R, would have a di¡er-
Fig. 3. The BPS domain of Grb10 inhibits phosphorylation of Shc
by IRKJ4P. The activity of puri¢ed IRKJ4P was assayed in the pres-
ence of the indicated concentrations of BPS^SH2R462K. Activity was
assayed using 200 nM IRKJ4P and 20 WM of Shc (see Section 2).
The reaction mixture was electrophoresed on a 12.5% polyacryl-
amide gel and the resulting autoradiograph is shown (top panel).
Band intensities were quanti¢ed and average intensities and stan-
dard deviations were determined. IRKJ4P activity in the presence of
BPS^SH2R462K is expressed as a percentage of the activity of
IRKJ4P alone (bottom panel).
Fig. 4. The BPS domain of Grb10 inhibits IGF1RK. The activity of
autophosphorylated IGF1RK was assayed in the presence of the in-
dicated concentrations of BPS^SH2R462K. Activity was assayed using
200 nM of IGF1RK and 1 mM of peptide substrate (see Section 2).
The mean and standard deviation are derived from triplicate experi-
ments. The activity of IGF1RK in the presence of BPS^SH2R462K is
expressed as a percentage of IGF1RK alone.
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ential e¡ect on substrate phosphorylation. Because Grb10 and
substrate proteins such as IRS1, Shc and p60 GAP-associated
protein are all recruited to the IR (or IGF1R) after receptor
activation, the degree to which a substrate protein is phos-
phorylated by the receptor will depend on how rapidly it is
recruited to the receptor vis-a-vis recruitment of Grb10 (and
other inhibitory proteins such as tyrosine phosphatases). Re-
ceptor recruitment is dependent on the particular modular
domains (SH2, PH, PTB) present in the substrate protein
(among other factors). Certain substrates are likely to trans-
locate to the activated IR relatively rapidly and would thus be
less susceptible to the inhibitory e¡ect of Grb10 than other
substrates.
An important clue to the physiological function of Grb10
comes from the discovery that the murine Grb10 gene is ma-
ternally imprinted [27]. Such genes typically encode proteins
that negatively regulate fetal growth [28]. Moreover, the loca-
tion of the human Grb10 gene on chromosome 7 [29] makes it
a candidate gene underlying Silver^Russell syndrome. This
disease is characterized by pre- and postnatal growth retarda-
tion and can be caused by maternal disomy of chromosome 7,
which potentially doubles the Grb10 dosage [27]. Our results
provide a direct physical mechanism by which Grb10 func-
tions as a negative regulator of insulin- and/or IGF1-mediated
signaling.
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